Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Payne

Internal Medicine Mechanicsville, VA Medical Doctor

NPI 1902872880 CMS profile 222858

7041 Lee Park Rd, Mechanicsville, VA 23111

Open in the dashboard

General payments

$7,033

461 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Payne of Mechanicsville, VA is reported in the CMS Open Payments database as having received $7,033 across 461 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $129 7
2024 General $212 12
2023 General $1,306 82
2022 General $1,840 115
2021 General $1,492 96
2020 General $944 69
2019 General $1,109 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Payne
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Charles Payne were reported at $129. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Charles Payne Internal Medicine median Middle half National median
2019 $1,109 $159 $48–$570 $163
2020 $944 $119 $33–$402 $114
2021 $1,492 $135 $37–$521 $132
2022 $1,840 $141 $42–$496 $149
2023 $1,306 $149 $45–$519 $160
2024 $212 $154 $47–$537 $164
2025 $129 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,383 95 payments
  2. Amgen Inc. $853 62 payments
  3. AbbVie, Inc. $583 41 payments
  4. Pfizer Inc. $477 33 payments
  5. Lilly USA, LLC $418 28 payments
  6. AstraZeneca Pharmaceuticals LP $363 19 payments
  7. Amarin Pharma Inc. $261 15 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $194 11 payments
  9. Otsuka America Pharmaceutical, Inc. $189 9 payments
  10. Novartis Pharmaceuticals Corporation $186 13 payments
  11. Other $2,128 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,014 460 payments
  2. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $778 50 payments
  2. RYBELSUS $704 45 payments
  3. Repatha $437 34 payments
  4. UBRELVY $419 27 payments
  5. Prolia $392 27 payments
  6. EVENITY $389 26 payments
  7. TRULICITY $331 22 payments
  8. FARXIGA $238 11 payments
  9. Vascepa $198 10 payments
  10. REXULTI $189 9 payments
  11. Other $5,866 379 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 174 drugs

Part D claims

11,156

Median for Internal Medicine: 777

Drug cost

$666,949

Median for Internal Medicine: $73,373

Branded share of claims

19.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 83 $117,148
Eliquis Apixaban Brand 91 $76,166
Farxiga Dapagliflozin Propanediol Brand 62 $65,170
Xarelto Rivaroxaban Brand 45 $63,227
Jardiance Empagliflozin Brand 42 $59,243
Tradjenta Linagliptin Brand 13 $20,428
Trulicity Dulaglutide Brand 12 $18,093
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $16,652
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 29 $14,815
Linzess Linaclotide Brand 12 $10,800

The 10 drugs with the highest cost, of 174 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$190,972

Of which drugs: $16,705

Medicare patients

593

Average age 78

Services billed

2,820

318 women, 275 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 34%
Diabetes 31%
Chronic kidney disease 31%
Atrial fibrillation 23%
Osteoporosis 21%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 117 117 $9,573
Pcv20 vaccine im 90677 Office 24 24 $6,821
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 11 40 $31

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $32
$32 — —
Ozempic
  • Novo Nordisk Inc $32
$32 83 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $17
$17 — —
UBRELVY
  • AbbVie, Inc. $14
$14 — —
QULIPTA
  • AbbVie, Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

461 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record